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ABSTRACT 
Transfersomes are particularly optimized, ultradeformable (ultraflexible) lipid supramolecular aggregates, which are able to 
penetrate the mammalian skin intact. Transfersome is a type of carrier system which is capable of transdermal delivery of low as 
well as high molecular weight drugs. Transfersomes penetrate through the pores of stratum corneum which are smaller than its size 
and get into the underlying viable skin in intact form. Acne vulgaris is a disease of the pilosebaceous follicle characterized by non-
inflammatory (open and closed comedones) and inflammatory lesions (papules, pustules, and nodules). In such situation transdermal 
drug delivery remains the most preferential mode of administration. But, stratum corneum forms the most formidable barrier for the 
penetration of drug through skin. To overcome the stratum corneum barrier, the use of lipid vesicles like transfersomes in delivery 
systems has involved increasing attention in recent years. The aim of the present study was to statistically optimize the vesicular 
formulations (Transfersomes) for enhanced skin delivery of a model drug Clindamycin Phosphate. 
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INTRODUCTION 
Acne vulgaris is a disease of the pilosebaceous follicle 
characterized by non-inflammatory (open and closed 
comedones) and inflammatory lesions (papules, 
pustules, and nodules). Its pathogenesis is multifactorial 
- the interplay of hormonal, bacterial, and 
immunological (inflammatory) factors results in the 
formation of acne lesions.
2
 Although acne is not a life-
threatening situation, it can have detrimental effects on 
the excellence of life of affected individuals. 
Fortunately, acne is readily approachable to the wide-
range of available medications, with the goals of therapy 
being to clear the lesions, prevent scarring, and limit any 
treatment-related side-effects. Clindamycin Phosphate is 
a antibiotic widely used for the treatment of acne. In oral 
dosage forms it produces pseudomonas colitis while in 
topical dosage forms it has side effects like irritation, 
skin rash, itching etc., it’s topical bioavailability is also 
less.
3,4 
So, to overcome these limitations an attempt has 
been made to prepare transfersomes of Clindamycin 
Phosphate and optimize it for enhanced delivery through 
the skin. The aim of the present study was to statistically 
optimize the vesicular formulations (Transfersomes) for 
enhanced skin delivery of a model drug of Anti-acne 
drug Clindamycin Phosphate, which was effective 
candidate for the treatment of acne.
1
 
METHODS 
Preformulation studies of clindamycin phosphate  
Preformulation studies are an important tool for 
determination of physical and chemical properties of the 
drug before incorporating it in formulation development 
programmed. 
5-9, 19-21
 
Physical appearance: The drug (clindamycin 
phosphate) powder was examined for its organoleptic 
properties like colour, taste and odour. 
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Solubility study: Solubility studies were performed in 
distilled water; 0.1N hydrochloric acid, ethanol, 
methanol, Phosphate buffer pH 7.4 at room temperature 
(25
 
± 2
0 
C). An excess amount of drug was added to 5 ml 
of solvent in screw-capped glass vials; these were 
mechanically shaken for 48 hours at 25° C until 
equilibrium was achieved. Aliquots were withdrawn, 
filtered through a membrane filter (0.45) and 
spectrophotometrically analyzed for solubility. 
FTIR Spectra of clindamycin phosphate:  IR spectra 
of physical mixture of drug and excipients were 
recorded by KBr method using Fourier Transform 
Infrared Spectrophotometer. A base line correction was 
made using dried potassium bromide pellet. The 
potassium bromide-drug pellet of approximately l mm 
diameter was prepared by grinding 3-5 mg of physical 
mixture of drug-excipients with 100-150 mg of 
potassium bromide in pressure compression machine. 
The sample pellet was mounted in IR compartment and 
scanned at wavelengths 4000 cm
-1
 to 400 cm
-1
. 
pH measurment: pH was determined by digital pH 
meter. In this method 1gm of clindamycin phosphate 
powder was accurately weighed and dissolved in 5 ml of 
ethanol and diluted to 100 ml with distilled water with 
sonication. The solution was filtered and pH of the 
filtrate was measured with digital pH meter. 
Melting point determination: It is one of the 
parameters for the purity of drugs. Melting point was 
determined digital melting point apparatus (Chemline 
CL-725). The sample (2-4 mg) was heated in a fuse 
capillary tube at a rate of 5ºC/min. 
Determination of Wavelength Maxima: Accurately 
weighed 10 mg of drug was dissolved in 100 ml of 
phosphate buffer pH 7.4 in a 100 ml volumetric flask. 
1 ml of this stock solution was pipetted into a 10 ml 
volumetric flask and volume made up to the mark 
with phosphate buffer pH 7.4. The resulting solution 
was scanned using UV/Vis double beam 
spectrophotometer.  
Preparation of calibration curve of clindamycin 
phosphate  
(a) Calibration curve in phosphate buffer pH 7.4: 10 
mg of clindamycin phosphate was weighed accurately 
and dissolved in 5 ml of methanol in a 100 ml of 
volumetric flask and volume was made up to 100 ml 
with the phosphate buffer pH 7.4. Aliquot of 1 ml of this 
solution was withdrawn and transferred to 10 ml 
volumetric flask and diluted to 10 ml with pH 7.4 
phosphate buffer to obtain a stock solution of 10g/ml. 
From this stock solution, aliquots of 1ml, 2ml 3ml 4 
ml……. 10 ml were transferred to 10 ml volumetric 
flasks and volume was made up to 10 ml phosphate 
buffer pH 7.4. Take 2 ml of this solution and add one ml 
methyl orange and extracted with 3 ml chloroform 
pipette out the chloroform layer and the absorbance of 
these solutions was measured at 486nm against a blank 
phosphate buffer pH 7.4. The calibration curve was 
obtained by plotting the absorbance of clindamycin 
phosphate versus the concentration of clindamycin 
phosphate. The straight line of best fit was obtained by 
using linear regression analysis program. 
Formulation and development  
Formulation development of Clindamycin phosphate 
loaded transfersomes
10-18
  
Soya-phosphatidylcholine, Span 80 (95:05, 90:10, 85:15, 
80:20, and 85:15) and Clindamycin phosphate (100mg) 
were dissolved alcohol. Then solution was put in a round 
bottom flask. These were then dissolved by shaking. 
Thin film was then formed by keeping it in the rotator 
vaccum evaporator at 40
0
C. Final traces of solvent are 
removed under vacuum. The deposited lipid film is 
hydrated with the appropriate buffer by rotation at 60 
rpm for 1 hour at room temperature. The resulting 
vesicles are swollen for 2 hours at room temperature. 
The multilamellar lipid vesicles (MLV) are then 
sonicated at room temperature. This thin film was then 
hydrated by phosphate buffer saline to get the 
transferosome. 
Table 1: Formulation code and variable used in 
preparation of transferosome 
S.No. Formulation code PC:S 
(mg) 
Drug 
(mg) 
1 TE1 95:05 100 
2 TE2 90:10 100 
3 TE3 85:15 100 
4 TE4 80:20 100 
5 TE5 80:20 100 
6 TE6 85:15 100 
SP=span 80, PC=phosphatidylcholine  
Preparation of Gels 
Preparation of carbopol gel base: 0.5 g Carbopol 934 
was weighed and dispersed in water with mild stirring 
and allowed to swell for 24 hours to obtain 0.5% gel. 
Later 2 ml of glycerin was added to for gel consistency. 
Similarly 1 and 2% carbopol gels were prepared. 
Table 2: Composition of different gel base 
Formulation Carbopol (%) 
TF1 0.5 
TF2 1.0 
TF3 2.0 
 
Preparation of transfersomes gels: 1g of transfersomes 
formulation was dissolved in 10ml of ethanol and 
centrifuged at 6000 rpm for 20 minutes to remove the 
unentrapped drug. The supernant was decanted and 
sediment was incorporated into the gel vehicle. 
The incorporation of the transfersomes into gels was 
achieved by slow mechanical mixing at 25 rpm for 10 
minutes. The optimized formulation was incorporated 
into three different gel concentration 0.5, 1 and 2% w/w. 
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Evaluation of clindamycin phosphate loaded 
transfersomes 
Microscopic observation of prepared 
transfersomes
10,11 
An optical microscope (cippon, Japan) with a camera 
attachment (Minolta) was used to observe the shape of 
the prepared transfersomes formulation.  
Vesicle size determination
12-13
:
 
Vesicle size was 
determined using the particle size analyzer (Malvern 
Master Sizer, Malvern Instruments Ltd., Malvern, UK)  
Entrapment efficiency
14-15
: Entrapment efficiency was 
determined by measuring the concentration of 
unentrapped free drug in aqueous medium. About 1 ml 
of the drug loaded transfersomes dispersion was placed 
in the Ependorf tubes and centrifuged at 10,000 rpm for 
30 min. The transfersomes along with encapsulated drug 
were separated at the bottom of the tubes. Plain 
transfersomes without Clindamycin phosphate was used 
as blank sample and centrifuged in the same manner. In 
order to measure the free drug concentration, the UV 
absorbance of the supernatant was determined at 486 
nm. 
Evaluation of Gels  
Determination of pH
16,17
: Weighed 50 gm of gel 
formulation were transferred in 10 ml of beaker and 
measured it by using the digital pH meter. pH of the 
topical gel formulation should be between 3–9 to treat 
the skin infections. 
Spreadability
17,21
: A modified apparatus suggested   
was used for determining spreadability. The 
spreadability was measured on the basis of slip and drag 
characteristics of the gels. The modified apparatus was 
fabricated and consisted of two glass slides, the lower 
one was fixed to a wooden plate and the upper one was 
attached by a hook to a balance. The spreadability was 
determined by using the formula: S=ml/t, where S, is 
spread ability, m is weight in the pan tied to upper slide 
and t is the time taken to travel a specific distance and l 
is the distance traveled. For the practical purpose the 
mass, length was kept constant and‘t’ was determined.  
The measurement of spreadability of each formulation 
was in triplicate and the average values are presented. 
Drug content
17,18
: 1 gm. of the prepared gel was mixed 
with 100 ml. of ethyl alcohol. Aliquots of different 
concentrations were prepared by suitable dilutions after 
filtering the stock solution and the absorbance was 
measured at 486 nm. Drug content was calculated by 
linear regression analysis of the calibration curve.  
In-vitro diffusion study
20,21
: An in-vitro drug release 
study was performed using modified Franz diffusion 
cell. Dialysis membrane (Hi Media, Molecular weight 
5000 Daltons) was placed between receptor and donor 
compartments. Transferosomal gel of Clindamycin 
Phosphate was placed in the donor compartment and the 
receptor compartment was filled with phosphate buffer, 
pH 7.4 (24 ml). The diffusion cells were maintained at 
37±0.5°C with stirring at 50 rpm throughout the 
experiment. At different time interval, 5 ml of aliquots 
were withdrawn from receiver compartment through 
side tube and analyzed for drug content by UV Visible 
spectrophotometer.  
Stability studies
20-21
: Optimized formulations of 
transfersomes gel were subjected to accelerated stability 
testing under storage condition at 4 ± 1C and at room 
temperature (28 ± 1C). Both formulations were stored 
in screw capped, amber colored small glass bottles at 4 ± 
1C and 28 ± 1C. Analysis of the samples were 
characterized for vesicle size and  drug content after a 
period of 7, 14, 21 and 28 days. 
(a) Effect of storage temperature on vesicle size: 
Subsequent change in vesicle size of the formulations 
stored at 4±1C and 28 ± 1C was determined using a 
Zetasizer (Malvern Instrument, UK) after a period of  7, 
14, 21 and 28 days. 
(b) Effect of storage temperature on drug content: 
After storage for a specified period of time of 7, 14, 21 
and 28 days, the drug content of both the formulations 
was determined. Drug content in transfersomes gel was 
determined spectrophotometrically to indirectly estimate 
the amount of drug entrapped in gel. 
RESULTS AND DISCUSSION 
Physiochemical Properties of Clindamycin phosphate 
Physical evaluation 
It refers to the evaluation by sensory characters-taste, 
appearance, odor, feel of the drug, etc. 
Table 3: List of Sensory characters 
S. No. Sensory characters Result 
1. 
Colour 
White to off white 
powder 
2. Odor Odorless 
3. Taste Tasteless 
 
Solubility: Solubility of the drug was determined by 
taking some quantity of drug (about 1-2 mg) in the test 
tube separately and added the 5 ml of the solvent (water, 
ethanol, methanol, 0.1N HCL, and 7.4 pH buffer) Shake 
vigorously and kept for some time. Note the solubility of 
the drug in various solvents (at room temperature).
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Table 4: Solubility of Clindamycin phosphate 
Solvent used Solubility I.P. Ranges 
Distilled  Water Slightly soluble 100 to1000 
0.1 N Hydrochloric acid Slightly soluble 100 to1000 
Ethanol Freely soluble 1 to 10 
Methanol Freely soluble 1to 10 
Phosphate buffer pH 7.4 Soluble 10 to 30 
 
Identification Test  
Sample of pure Clindamycin 
The IR spectrum of sample drug shows the peak values which are characteristics of the drug and the graph were shown 
in figure no. 7.1 
 
Figure 1: FT-IR spectrum of pure drug (Clindamycin phosphate) 
Table 5: Interpretation of Clindamycin phosphate 
Sr. No. Wave Number of drug (cm
-1
) Interpretation 
1. 1651.49 C=O Stretching 
2. 1386.64 C-N Stretching 
3. 2927.79 C-H 
4. 3468.71 O-H 
 
Melting point: 
Table 6: Melting point of the Clindamycin phosphate 
S. No. Melting Point of Clindamycin phosphate Average Melting Point of Clindamycin phosphate 
1. 
2. 
3. 
140-142
o
C 
141-142
o
C  
140-142
o
C 
140-142
o
C 
 
Determination of λ max of Clindamycin phosphate: 
The λmax of Clindamycin phosphate was determined by running the spectrum of drug solution in double beam 
ultraviolet spectrophotometer. 
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Figure 2: Wavelength maxima of Clindamycin 
phosphate buffer pH 7.4 
Calibration curve of Clindamycin phosphate at λ max 
486nm 
Table 7: Calibration curve of Clindamycin 
phosphate 
S. No. Conc. (µg/ml ) Absorbance 
1 10 0.109 
2 20 0.247 
3 30 0.389 
4 40 0.519 
5 50 0.664 
 
 
Figure 3: Calibration curve of Clindamycinin 
phosphate buffer pH 7.4 at 486nm 
The linear regression analysis was done on Absorbance 
data points. The results are as follow for standard curve  
     Slope = 0.015 
     The intercept = 0.005 
     The correlation coefficient (r
2
) = 0.999 
Compatibility studies of drug and excipients 
In the compatibility testing program, blends of drug and 
excipients are prepared by triturating the drug with 
Individual excipients. 
Procedure: Taken 50 mg accurately weigh of 
clindamycin phosphate dry powder and 50 mg of 
excipients and mix the blend of drug and excipients and 
binary/tertiary blends of extract and excipients were 
prepared and transferred to inert glass vials. The mouths 
of the vials were covered with rubber closures followed 
by the aluminum seal caps. Binary/tertiary blends of 
extract and excipients, clindamycin neat and excipients 
were stored at 4˚C (refrigerator) as control and at 
40˚C/75%RH for accelerated stability studies for 4 
weeks. The λmax were recorded for determination of 
Compatibility of clindamycin phosphate with other 
excipients. 
 
Figure 4: Wavelength maxima of Clindamycin 
phosphate 
 
Figure 5: Wavelength maxima of Clindamycin 
phosphate + Excipients
 
Table: Comparative data of preformulation studies of clindamycin phosphate 
Parameter Observation 
Melting Point 140-142
o
C 
pH (1 w/v solution) 7.8 
Hausner ratio 1.28  
Solubility  Freely soluble in Ethanol, Methanol. Soluble in Phosphate Buffer 7.4, slightly 
soluble in water and 0.1 N HCL.   
Loss on Drying (%) 0.72 
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The preliminary study showed that clindamycin 
phosphate is white, crystalline, odorless powder. It is 
freely soluble in Ethanol, Methanol. Soluble in 
Phosphate Buffer 7.4, slightly soluble in water and 0.1 N 
HCL. The melting point was in the range of 140-142
o
C 
which is in compliance with the standard value of 140-
142
o
C.        
From the FTIR data of the physical mixture it is clear 
that functionalities of drug have remained unchanged 
including intensities of the peak. This suggests that 
during the process drug and cholesterol has not reacted 
with the drug to give rise to reactant products.  So there 
is no interaction between them which is in favor to 
proceed for formulation of vesicular drug delivery 
system. The U.V study shows that the drug and 
Excipient are compatible with each other.  
Results of Evaluation of transfersomes 
Microscopic observation of prepared transfersomes 
An optical microscope (cippon, Japan) with a camera 
attachment (Minolta) was used to observe the shape of 
the prepared transfersomes formulation.  
 
       
 T1                                       T2                                 T3  
   
T4                                       T5                               T6  
Figure 6: Microscopic observation of transfersomes formulations  
 
Evaluation of Vesicle size and Entrapment efficiency 
Table includes the value of vesicle size, and entrapment 
efficiency. The vesicle size of all transfersomes varied 
between 178.89 and 245.65 nm where as entrapment 
efficiency was found between 61.15 to 75.65%. 
 Table: 9: Evaluations of transfersomes for Vesicle size and Entrapment efficiency 
Formulation Vesicle Size (nm) Entrapment efficiency (%) 
T1 198.89±0.85 70.56±1.25 
T2 178.50±0.21 75.65±1.98 
T3 210.56±1.24 69.98±1.65 
T4 225.65±0.98 61.15±1.23 
T5 241.32±0.65 65.65±1.45 
T6 245.65±0.78 68.98±1.32 
 
Results showed that in formulation T2 which contain 
smallest vesicle size and increase in entrapment 
efficiency, Formulation T2 Sleeted as optimized 
formulation for further evaluation. 
 
Thakur et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2018; 8(5):168-177           
ISSN: 2250-1177                                                                             [174]                                                                             CODEN (USA): JDDTAO 
 
 
Figure 7: Vesicle Size of Optimized transfersomes 
formulation T2 
 
Figure 8: Zeta potential of Optimized transfersomes 
formulation T2
 
Table 10:  Vesicle size and entrapment efficiency of optimized formulation 
Formulation Code Vesicle Size (nm) Entrapment 
Efficiency (%) 
Zeta potential 
(mV) 
T2 178.5 73.70±0.995 - 48.5  
 
Evaluation of Transfersomes Gel 
Drug content: Drug content is most important in 
transfersomes formulation and the data found are 
satisfactory. It was found to be 95.65 to 97.98% which 
shows the good capacity of formulation to hold the drug. 
The maximum drug content was found in formulation 
TG-2 (97.98%) 
pH: In transdermal drug delivery system pH plays an 
important role, the result of transfersomes formulation 
shows that all the formulations are suitable for skin 
delivery. The pH value of the prepared transfersomes 
gels was found to be in limits of 6.87-6.99. The pH of 
optimized formulation TG-2 was found to be 6.99. 
Spreadibility: A modified apparatus was used for 
determining spreadability. The spreadability was 
measured on the basis of slip and drag characteristics of 
the gels and was in the range of 11.65 – 13.25 gms. cm. 
/sec. The gels should have optimum spreadability 
because very high and very low spreadability values 
indicate that the application of the gel to the site is 
difficult. The spreadability of optimized formulation 
TG-2 was found to be 12.65. 
Viscosity measurements: The viscosity of gels was 
determined by using a Brookfield viscometer DV-II 
model. T-Bar spindle in combination with a helipath 
stand was used to measure the viscosity and have 
accurate readings.  
Five readings taken over a period of 60 seconds were 
averaged to obtain viscosity. The Viscosity of optimized 
formulation was found to be 2369cps. 
 
Table 11: Results of transfersomes gel formulations 
 Code Drug content 
 (%) 
pH Spreadability 
(Gm.cm/sec.) 
Viscosity  
(cps) 
TG1 95.65±0.12 6.98±0.12 13.25±1.25 2658±15 
TG 2 97.98±0.15 6.99±0.15 12.65±1.23 2369±22 
TG 3 96.56±0.25 6.87±0.08 11.65±1.56 2154±25 
 
 
In-vitro drug release study: In-vitro diffusion study of 
the transfersomes gel (TG1, TG2, and TG3) was 
performed using modified Franz diffusion cell with 
dialysis membrane in phosphate buffer pH 7.4 for a 
period of 10 hours. The data obtained from diffusion 
studies are summarized in Table. The release rate of 
drug from transfersomes formulation over dialysis 
membrane was significantly higher than its transport 
across skin, indicating the barrier properties of skin for 
drugs.  The in vitro release data were fitted into different 
kinetic models viz Zero-order, First order, Higuchi 
model and Korsmeyer Peppas equation. Zero-order 
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plots, First order plots, Higuchi plots and Korsmeyer 
Peppas plots are shown in Figure. The zero-order plots 
were found to be fairly linear. In order to determine the 
exact mechanism of drug release from salicylic acid gel 
the in vitro release data were fitted to Korsmeyer Peppas 
equation and the ‘n’ values were calculated. ‘n’ values 
were found to be in the range of 0.5<n<1.0, which 
suggests that the drug release mechanism from the gel 
followed non-Fickian diffusion mechanism (Anamolous 
transport). Transfersomes gel released drug in controlled 
release manner in 8 hour but in case of marketed 
formulation there is no controlled release of drug from 
gel. The release of the drug from transfersomes gel was 
found to follow the order:  
TG2> TG3> TG1
 
 In-vitro drug release data of transfersomes gel formulation  
Table 12: In-vitro drug release data for TG2 
Time 
(h) 
Square Root 
of Time(h)
1/2
 
Log 
Time 
Cumulative* % 
Drug Release 
Log 
Cumulative % 
Drug Release 
Cumulative % 
Drug 
Remaining 
Log Cumulative 
% Drug 
Remaining 
0.5 0.70711 -0.301 20.25 1.306 79.75 1.902 
1 1 0.000 40.56 1.608 59.44 1.774 
2 1.41421 0.301 48.98 1.690 51.02 1.708 
4 2 0.602 69.98 1.845 30.02 1.477 
6 2.44949 0.778 75.65 1.879 24.35 1.386 
8 2.82843 0.903 89.98 1.954 10.02 1.001 
10 3.16228 1 95.56 1.980 4.44 0.647 
*Average of three reading 
 
Figure 9: Cumulative % drug released Vs Time  
 
Figure 10: Log cumulative % drug remaining Vs 
Time  
 
Figure 11: Cumulative % drug released Vs Square 
root of Time  
 
Figure 12: Log cumulative % drug released Vs log 
Time
  
Table 13: Regression analysis data of transfersomes gel formulation 
Batch 
Zero Order First Order Higuchi’s Model 
Korsmeyers Peppas 
Equation 
R² R² R² R² 
TG2 0.941 0.891 0.974 0.956 
 
Thakur et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2018; 8(5):168-177           
ISSN: 2250-1177                                                                             [176]                                                                             CODEN (USA): JDDTAO 
Stability studies: Stability studies for optimized 
formulations were carried out at 4.0  0.5C and 28 ± 
0.5ºC for a period of four weeks. There was no 
significant variation found in physical appearance, 
average particle size and % drug content of the 
transfersomes gel. 
SUMMARY AND CONCLUSION 
The preliminary study showed that clindamycin is 
white, crystalline, odorless powder. It is freely soluble 
in Ethanol, Methanol. Soluble in Phosphate Buffer 7.4, 
slightly soluble in water and 0.1 N HCL. The melting 
point was in the range of 140-142
o
C which is in 
compliance with the standard value of 140-142
o
C.        
From the FTIR data of the physical mixture it is clear 
that functionalities of drug have remained unchanged 
including intensities of the peak. This suggests that 
during the process drug and cholesterol has not reacted 
with the drug to give rise to reactant products.  So there 
is no interaction between them which is in favor to 
proceed for formulation of vesicular drug delivery 
system. The U.V study shows that the drug and 
Excipient are compatible with each other.  
Total Six formulations were prepared using varying 
amount of Soya-phosphatidylcholine, Span 80 and drug 
and evaluated for Vesicle size and Entrapment 
efficiency. Formulation T2 which contain smallest 
vesicle size and increase in entrapment efficiency, 
Formulation T2 Sleeted as optimized formulation for 
further evaluation. 
The optimized batch of Transfersomes was further 
incorporated into gel base and evaluated for pH, 
Spreadability, Measurement of viscosity, Drug content 
and In-vitro diffusion study.  
Drug content is most important in transfersomes 
formulation and the data found are satisfactory. It was 
found to be 95.65 to 97.98% which shows the good 
capacity of formulation to hold the drug. The maximum 
drug content was found in formulation TG-2 (97.98%) 
In transdermal drug delivery system pH plays an 
important role, the result of transfersomes formulation 
shows that all the formulations are suitable for skin 
delivery. The pH value of the prepared transfersomes 
gels was found to be in limits of 6.87-6.99. The pH of 
optimized formulation TG-2 was found to be 6.99. 
A modified apparatus was used for determining 
spreadability. The spreadability was measured on the 
basis of slip and drag characteristics of the gels and was 
in the range of 11.65 – 13.25 gms. cm. /sec. The gels 
should have optimum spreadability because very high 
and very low spreadability values indicate that the 
application of the gel to the site is difficult. The 
spreadability of optimized formulation TG-2 was found 
to be 12.65 
The best method for the selection of spindle was trial 
and error starting from T91 spindle. Spindles in 
increasing number were used depending on the % torque 
and error. The goal is to obtain a viscometer dial or 
display (% torque) reading between 10 & 100, the 
relative error of measurement improves as the reading 
approaches 100. Spindle T 95 was found to be suitable 
and was used for the measurement of viscosity of all the 
gels. The Helipath T- Bar spindles were rotated up and 
down in the sample giving variable viscosities at a 
number of points programmed over the time. Five 
readings taken over a period of 60 seconds were 
averaged to obtain viscosity. The Viscosity of optimized 
formulation was found to be 2369cps. 
Stability studies for optimized formulations were carried 
out at 4.0  0.5C and 28 ± 0.5ºC for a period of four 
weeks. There was no significant variation found in 
physical appearance, average particle size and % drug 
content of the transfersomes gel. 
From this study, it was concluded that the optimized 
batch of clindamycin, with high EE% and small particle 
size. Also, the preparation of clindamycin as 
transfersomal gel has the ability to overcome the barrier 
properties of the skin and increase the drug release. 
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